Location History:
- Salisbury, GB (2007 - 2015)
- Wrexham, GB (2018)
- Oxon, GB (2013 - 2020)
- Abingdon, GB (2010 - 2022)
Company Filing History:
18 out of 36 
7 out of 2,285 
5 out of 27 
Years Active: 2007-2022
Title: The Inventive Journey of Philip Marks: A Leader in Clostridial Neurotoxin Research
Introduction: Philip Marks, hailing from Salisbury, GB, is a distinguished inventor with a remarkable portfolio of 26 patents. His innovative contributions primarily focus on the field of biochemistry and therapeutic applications, particularly concerning activated clostridial neurotoxins.
Latest Patents: Among his latest patents, Philip has developed multiple groundbreaking methods and compositions. These include the "Production of Activated Clostridial Neurotoxins," focusing on techniques for producing activated clostridial neurotoxins. In addition, he has pioneered a "Method of Treatment Using a Composition Comprising an Activated Clostridial Neurotoxin," which details advancements in utilizing clostridial neurotoxins for therapeutic purposes. His work on "Suppression of Prostate Cancer Using a Targeted Clostridial Neurotoxin" introduces innovative methods for treating various cancers, particularly colorectal, breast, prostate, and lung cancers. This research encompasses the use of non-cytotoxic proteases targeted at hormone-secreting cells, effectively inhibiting harmful cell signaling related to cancer progression.
Career Highlights: Philip has made significant contributions while working at notable companies, including Syntaxin Limited and Allergan, Inc. His expertise has led to advancements in biopharmaceuticals and therapeutic interventions using neurotoxins. Through his career, he has continuously sought to harness the potential of clostridial toxins for medical applications, reinforcing his status as a leading figure in this domain.
Collaborations: In his professional journey, Philip has collaborated with renowned coworkers, including Keith Foster and John Andrew Chaddock. Their collective efforts have contributed to the successes and advancements in their shared research areas, significantly impacting therapies and treatment methodologies.
Conclusion: Philip Marks exemplifies the spirit of innovation in the field of biochemistry, particularly through his extensive research and patent portfolio on activated clostridial neurotoxins. His work continues to pave the way for novel therapeutic treatments, offering hope for patients suffering from various cancers and further advancing the scientific community’s understanding of neurotoxin applications.